SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

PharmaEssentia Reports Preclinical Data on Two Solid-Tumor Programs

PharmaEssentia reported preclinical data at SITC on PEC2001, a dual LILRB1/2 antagonist, and PEC3001, a PD-1-targeted IL-2 immunocytokine. The data support advancement toward IND-enabling and first-in-human studies.

6446

Related stories